Regeneron Pharmaceuticals is showing a significant technical reversal pattern according to market analysis. The large-cap biotech stock could see 15% upside if the pattern completes as projected.
Life science giant Thermo Fisher Scientific makes a massive $9.4 billion move into clinical trial software. The acquisition of Clario represents a strategic pivot toward digital endpoints and AI-powered drug development analytics.
The Biosecure Act represents a major shift in US-China scientific relations. While addressing security concerns, it threatens to disrupt critical research collaborations and supply chains essential for American biotech leadership.
